# A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD

> **NCT01946620** · PHASE3 · COMPLETED · sponsor: **Mundipharma Research Limited** · enrollment: 1767 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Flutiform
- **DRUG:** Formoterol

## Key facts

- **NCT ID:** NCT01946620
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2016-04
- **Final completion:** 2016-05
- **Target enrollment:** 1767 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01946620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01946620, "A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01946620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*